In a groundbreaking clinical trial presented at the 2024 Conference on Retroviruses and Opportunistic Infections, a weekly injection of semaglutide demonstrated both safety and efficacy in reducing liver fat in patients with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD). This phase-IIb pilot study enrolled 49 participants with HIV and MASLD, and varying demographics and antiretroviral therapy regimens, achieving an impressive 31% average reduction in liver fat and a noteworthy 29% of participants experiencing complete resolution of MASLD at 24 weeks.
The self-administered weekly injection of semaglutide was well-tolerated, with gastrointestinal side effects being the most common. The study suggests that semaglutide could potentially be a safe and effective therapeutic option for addressing MASLD in individuals with HIV, offering insights into healthier aging…
